Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AVP-04
- Development stage
- Unknown
- Lead developer
- Avipep
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
AVP-04 (also known as AVP0458) is an antibody-drug conjugate (ADC) developed by Avipep, utilizing their proprietary "Avibody" platform. It consists of a compact antibody fragment targeting Tumor-Associated Glycoprotein 72 (TAG-72), also known as CA72-4 or Sialyl-Tn, which is highly expressed in various adenocarcinomas. The Avibody is conjugated to cytotoxic payloads such as PEG-vc-DM1 (a maytansinoid) or TCO-MMAE. A radiolabeled version, 124I-PEG-AVP04, has been evaluated in Phase 1 clinical trials for PET imaging to assess tumor biodistribution in patients with relapsed prostate cancer. The therapeutic candidate is being explored for the treatment of ovarian, gastric, and colon cancers.
- Other names
- PEG-AVP04PEG-AVP-04PEG-AVP 04ADC-AVP04ADC-AVP-04ADC-AVP 04ADC AVP04124I-PEG-AVP04
02
Targets
TUBB (Tubulin (alpha and beta subunits))TAG-72
Beyond the preview
Go deeper on AVP-04.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AVP-04.